The 18 most recent market catalysts affecting $ILMN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 85
U.S. FDA Advisers Back Safety Of GRAIL's Galleri Multi-Cancer Screening Test; FDA Advisers Vote 6-4 That GRAIL's Galleri Is Effective For Proposed Use In Multi-Cancer Screening Test; Advisers Vote 7-2, With One Abstention, That Benefits Of GRAIL's Galleri Test Outweigh Risks For Proposed Use
FDA advisers have given a strong endorsement to GRAIL's Galleri multi-cancer screening test, voting favorably on both its safety and efficacy for its proposed use. This is a critic…
Sep 21, 2026
Corporate Catalyst
Neutral
Impact 75
The FDA Posted Briefing Documents For Grails Galleri Test Review Ahead Of The Molecular And Clinical Genetics Panel Of The Medical Devices Advisory Committee That Is Being Held On September 23; Flags No Major Concerns For Co's Cancer Test
The FDA's posting of briefing documents for GRAIL's Galleri test review, specifically noting 'no major concerns,' is a significant development. This suggests a smoother path toward…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 65
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
The filing details several analyst upgrades, with the most significant being UBS's upgrade of Illumina (ILMN) from Neutral to Buy and a substantial price target increase from $135 …
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 75
UBS Upgrades Illumina to Buy, Raises Price Target to $260
UBS analyst Doug Schenkel upgraded Illumina (ILMN) from Neutral to Buy and raised the price target from $135 to $260. This significant upgrade from a major investment bank indicate…
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 55
Argus Research Maintains Buy on Illumina, Raises Price Target to $235
Argus Research analyst Jasper Hellweg maintained a 'Buy' rating on Illumina and significantly raised the price target from $180 to $235. This action indicates a stronger conviction…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Sell on Illumina, Raises Price Target to $113
This filing discloses that Citigroup's analyst Joanne Wuensch has maintained a 'Sell' rating on Illumina (ILMN), but has also raised the price target from $95 to $113. This action …
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
Piper Sandler Reiterates Overweight on Illumina, Raises Price Target to $225
Piper Sandler analyst David Westenberg has reiterated an 'Overweight' rating on Illumina (ILMN) and raised the price target from $200 to $225. This action signals continued confide…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Illumina, Raises Price Target to $230
RBC Capital's analyst Dan Leonard has maintained an 'Outperform' rating on Illumina and raised the price target from $170 to $230. This upward revision in the price target, a subst…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Illumina, Raises Price Target to $230
JP Morgan analyst Casey Woodring has maintained an 'Overweight' rating on Illumina and raised the price target from $220 to $230. This action signals continued confidence in Illumi…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Hold on Illumina, Raises Price Target to $210
TD Cowen analyst Dan Brennan raised the price target for Illumina (ILMN) from $192 to $210, while keeping a 'Hold' rating. This adjustment suggests a slightly improved valuation ou…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 75
Illumina shares are trading lower after the company reported its Q2 financial results. The stock initially rallied yesterday after the market closed, but it has since reversed.
The headline points to a corporate catalyst – Illumina's Q2 financial results – as the primary driver of its stock movement. The initial rally followed by a reversal suggests that …
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Illumina, Raises Price Target to $226
Guggenheim analyst Subbu Nambi maintained a 'Buy' rating on Illumina (ILMN) and raised the price target from $200 to $226. This action signals a strengthened positive outlook from …
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Stifel Maintains Buy on Illumina, Raises Price Target to $225
This filing indicates that Stifel, through its analyst Daniel Arias, has reaffirmed its 'Buy' rating for Illumina (ILMN) and substantially raised its price target from $155 to $225…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Underweight on Illumina, Raises Price Target to $160
This filing discloses that Barclays analyst Luke Sergott has maintained an 'Underweight' rating on Illumina (ILMN) while simultaneously raising the price target from $145 to $160. …
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 92
Illumina shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance above estimates.
Illumina's better-than-expected Q2 results and significantly raised FY26 guidance are a major positive catalyst for the company. This indicates strong underlying business fundament…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Illumina Q2 Adj. EPS $1.31 Beats $1.23 Estimate, Sales $1.159B Beat $1.130B Estimate
This headline represents a significant positive corporate catalyst for Illumina. Beating both EPS and revenue estimates indicates robust underlying business performance, likely dri…
Jul 17, 2026
Corporate Catalyst
Bullish
Impact 60
Leerink Partners Maintains Outperform on Illumina, Raises Price Target to $210
Leerink Partners analyst Puneet Souda has maintained an 'Outperform' rating on Illumina (ILMN) and raised the price target from $175 to $210. This action signals increased confiden…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Hold on Illumina, Raises Price Target to $190
Canaccord Genuity analyst Kyle Mikson has raised the price target for Illumina (ILMN) from $140 to $190, while simultaneously maintaining a 'Hold' rating. This indicates that while…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.